The group's principal activity is to develop and market individualized therapies and small molecules for the treatment of cancer and other life-threatening diseases. The group also offers biological manufacturing services to other biotechnology and pharmaceutical companies. The group's patented autologous cell technology ac vaccine attempts to stimulate a patient's own immune system to recognize, contain and eliminate cancer cells. The ac vaccine products include m-vax and o-vax. M-vax is designed as an immunotherapy for the post-surgical treatment of late stages melanoma. O-vax is designed as an immunotherapy for the treatment of ovarian cancer. The group is a development stage and operates in the United States, France & Australia.